CA-SOLIDIGM
26.4.2022 18:02:05 CEST | Business Wire | Press release
Today Solidigm is expanding its performance-optimized D7 Product Series with new solid-state storage drives (SSDs) — the D7-P5520 and the D7-P5620 — for data center and enterprise use. These drives are optimized for real-world compute and storage server workloads and are available in an extended range of form factors and capacities. They offer accelerated performance and reduced total cost of ownership (TCO) by enabling a smaller storage footprint and lower power consumption.
The D7-P5520 (designed for read-intensive and light mixed workloads), and the D7-P5620 (designed for mixed workloads), are the first family of products being introduced by Solidigm, which launched as a standalone company in December 2021.
The D7 Series comprises the industry’s most advanced PCIe 4.0 SSD family of products given their capacity offerings, breadth of form factors and optimized performance capabilities. These SSDs are optimized for real-world workloads and reflect insights gained from deep technical engagements with leading cloud service providers, OEMs, and storage innovators. Designed and tested with zero tolerance for data errors, consistently durable IOPS and QoS, and with near-zero lifetime performance degradation, they can be deployed with the utmost confidence.
“Our deep technical engagements spanning all industry segments give us unique customer insights to optimize our products,” said David Dixon, SVP and General Manager, Data Center, Solidigm. “The D7-P5520 and the D7-P5620 are the culmination of these insights and of multiple 3D NAND and PCIe 4.0 generations, which enable us to deliver a best-in-class offering and a new paradigm in solid-state storage.”
ByteDance partnered with Solidigm early in product development and qualified the D7-P5520 with outstanding results before live deployment in March 2022. The drives are delivering a breadth of capacity and performance improvements over prior generations, which has allowed them to boost performance by 33% with dramatic TCO improvement for database and cloud software-defined storage. The D7-P5520 will also be used in ByteDance’s public cloud services platform Volcano Engine.
Key Benefits:
-
Accelerated performance
across a range of workloads:
- D7-P5520 : up to 42% higher 4K Random Reads, 17% higher 4K Random Writes, with up to 43% better latency generation to generation. It also delivers up to 40% better read responsiveness in the presence of write pressure as compared to the competition, a key consideration for real-world workloads.
- D7-P5620: up to 56% 4K higher Random Reads, and up to 53% higher Random Writes, with up to 29% better latency generation to generation.
- Total cost of ownership (TCO) can be reduced through the combination of higher performance and expanded capacities. For example, OEMs designing for a 10M IOPS 2U server can reduce the storage footprint up to 27% while reducing power consumption up to 20% generation over generation.
- The D7 Series can be used in a wide array of storage configurations , including 1U and 2U tiered and monolithic configurations in compute and storage servers. The drives are available with extended capacity ranges and in multiple form factors, including E1.L and multiple E1.S offerings.
- Qualifications can be streamlined since Solidigm’s D7-P5520 and D7-P5620 family of products share common NAND, firmware, and controllers across SKUs.
- Quality and reliability are designed into these drives. For example, extra firmware checks are added to validate that data was saved accurately in the event of power loss. Additionally, the drives have been rigorously tested beyond industry specifications and common industry practices.
Visit solidigm.com for more information on the D7-P5620, the D7-P5520, and the full D7 Series, tuned for real-world mixed and performance-sensitive workloads. You can also learn more during a live webinar on June 15, 2022, 9 a.m. PT. Information and registration .
ABOUT SOLIDIGM
Solidigm is a leading global provider of innovative NAND flash memory solutions. Solidigm technology unlocks data’s unlimited potential for customers, enabling them to fuel human advancement. Our origins reflect Intel’s longstanding innovation in memory products and SK hynix’s international leadership and scale in the semiconductor industry. Solidigm became a standalone U.S. subsidiary under SK hynix in December 2021. Headquartered in San Jose, CA, Solidigm is powered by the inventiveness of close to 2,000 employees in 20 locations around the world. For more information, please visit solidigm.com and follow us on Twitter at @Solidigm and on LinkedIn .
All products, computer systems, dates, and figures specified are preliminary based on current expectations, and are subject to change without notice.
Tests document performance of components on a particular test, in specific systems. Differences in hardware, software, or configuration will affect actual performance. Consult other sources of information to evaluate performance as you consider your purchase.
Performance results are based on testing as of dates shown in the configurations and may not reflect all publicly available updates. See configuration disclosure for details. No product or component can be absolutely secure.
Solidigm optimizations, for Solidigm compilers or other products, may not optimize to the same degree for non-Solidigm products.
Solidigm technologies may require enabled hardware, software, or service activation.
Your costs and results may vary.
© Solidigm. “Solidigm” is a trademark of SK hynix NAND Product Solutions Corp. “Intel” is a registered trademark of Intel Corporation. Other names and brands may be claimed as the property of others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005470/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
